Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.57 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.52 |
| ▸ | HTR5A | P47898 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | RXRB | P28702 | 2/20 | 0.50 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.50 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222146 | 1.00 | KAT6A (0.57) | KAT6AKMOHTR1AADORA3CCKAR | |
| Benzoic Acid SCHEMBL26966093 | 0.89 | DAO (0.54) | KAT6AKMOHTR1AADORA3CCKAR | |
| SCHEMBL27623947 | 0.87 | KAT6A (0.55) | KAT6AHTR1AADORA3CCKARHTR5A | |
| SCHEMBL27905638 | 0.86 | KAT6A (0.58) | KAT6AKMOHTR1AADORA3CCKAR | |
| SCHEMBL28656241 | 0.85 | KAT6A (0.46) | KAT6AKMOHTR1AADORA3CCKAR | |
| SCHEMBL4052204 | 0.84 | FYN (0.57) | KAT6AHTR1AADORA3CCKARHTR5A | |
| SCHEMBL4559856 | 0.84 | AR (0.52) | KAT6AHTR1AADORA3CCKARHTR5A | |
| SCHEMBL6040460 | 0.84 | KAT6A (0.47) | KAT6AKMOHTR1AADORA3CCKAR | |
| SCHEMBL420705 | 0.83 | KDM4E (0.55) | SRPK1RPS6KB2HDAC2KDM4EPOLB | |
| SCHEMBL29860752 | 0.81 | KAT6A (0.50) | KAT6AHTR1AADORA3CCKARHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | claimed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | claimed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | claimed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | claimed |
| US-8586746-B2 | Amino-aza-adamantane derivatives and methods of use | ABBVIE INC. (US) | 2013-11-19 | — | — | US | claimed |
| EP-2476681-A2 | Amino-aza-adamantane derivatives and methods of use | Abbott Laboratories (US) | 2012-07-18 | — | — | EP | claimed |
| WO-2009055631-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-30 | — | — | WO | claimed |
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| EP-4405334-A1 | SORTILIN INHIBITORS | Sortina Pharma AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| CN-118317947-A | Sortilin inhibitors | 索蒂纳制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| CN-1376153-A | Amide compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-23 | — | — | CN | disclosed |
| EP-1216240-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001025229-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | KAT6A 1807/4885KMO 641/4885HTR1A 42/4885 |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | KAT6A 4162/4885KMO 4685/4885HTR1A 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.